v3.25.4

SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS (Details) (Parenthetical) - $ / shares | Sep. 30, 2025 | Dec. 31, 2024 | Dec. 31, 2023
--- | --- | --- | ---
Common stock par value | $ 0.0001 | $ 0.0001 |
Aspire Biopharma Inc [Member] |  |  |
Common stock par value |  | $ 0.00005 | $ 0.00005
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member] |  |  |
Common stock par value |  |  | $ 0.001

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=ASBP_AspireBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |